Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
A prospective multicenter surveillance program on yeast bloodstream infections was implemented in the Paris, France, area without restrictions on ward of hospitalization (intensive care unit, hematology, and surgery) or age (adults and children). The present analysis concerns 2,618 isolates collected over 7 years from 2,441 patients. Centralized species identification and antifungal susceptibility testing using the EUCAST methodology were performed. Almost 10% (232/2,441) of the patients had recently (≤30 days) been treated with antifungal drugs. We analyzed the effect of recent exposure to fluconazole ( n = 159) or caspofungin ( n = 61) on the proportions of the five major Candida species. For both drugs, preexposure was associated with a decreased prevalence of Candida albicans in favor of less drug-susceptible species ( C. glabrata and C. krusei for the former and C. parapsilosis and, to a lesser extent, C. glabrata and C. krusei for the latter; P = 0.001). In the multivariate analysis, the risk of being infected with an isolate with decreased susceptibility to fluconazole was independently associated with an age of ≥15 years (odds ratio [OR] = 2.45; 95% confidence interval [CI] = 1.39 to 4.31; P = 0.002) and with recent exposure to fluconazole (OR = 2.17; 95% CI = 1.51 to 3.13; P < 0.001), while the risk of being infected with an isolate with decreased susceptibility to caspofungin was independently associated with an age <15 years (OR = 2.53; 95% CI = 1.43 to 4.48; P = 0.001) and with recent exposure to caspofungin (OR = 4.79; 95% CI = 2.47 to 9.28; P < 0.001). These findings could influence future recommendations for the management of candidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, Candida spp. distribution may not vary only between geographical regions, but even between medical centers in close proximity, perhaps affected by factors influencing local epidemiology including prior antifungal exposure and patient age within the ICU.67”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [67]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent exposure to an echinocandin was found to significantly increase the risk of infection with C. parapsilosis [85].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [85]
In the citing paper
“Often, for naturally susceptible species, both the relative amount of resistant strains and the overall MIC levels in clinical isolates increase after the continuous use of a given antifungal drug [44].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [44]
In the citing paper
“Quite soon after the introduction of the echinocandins it was noted that the increasing use was accompanied by epidemiological shifts with a proportional or numeric increase in the less susceptible C. parapsilosis at several centres (8;17;18).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [8]
In the citing paper
“A consequence of enhanced drug exposure is increased selection pressure for resistance and indeed an altered species distribution for invasive infections has been linked to the echinocandin use (8).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 4×
“ysis of susceptibility profiles can occur (30).”
BackgroundResultInfluentialInternational Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“The 2009 updated guidelines of the Infectious Diseases Society of America (IDSA) recommend that an echinocandin or fluconazole be used as first-line therapy for candidemia before identification of the causative species in nonneutropenic patients (27) and that an echinocandin be used in the case of exposure to fluconaz…”
BackgroundPosaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 1×
“caspofungin or fluconazole, the two major drugs recommended for the first-line treatment of candidemia and for preemptive/ prophylactic treatment in high-risk patients, was associated with changes in the epidemiology of the infection (22, 28).”
BackgroundPosaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,345
Horn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956 · cited 1×
“In addition, they have been associated with reduced survival in cancer patients with recent azole administration (17, 38, 45).”
BackgroundWingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937 · cited 2×
“krusei) to fluconazole is observed in hematology populations receiving prolonged fluconazole prophylactically (24, 46) as well as in ICU populations (6, 33).”
BackgroundCandida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S. (1997) · Clinical Infectious Diseases · doi:10.1086/513663 · Cited by 755 · cited 1×
“The relationship between the increased incidence of these species and fluconazole prescription has been debated ever since the introduction of fluconazole as prophylaxis in hematology wards (1, 15, 33, 46) and in ICUs (14).”
Background
Research works printed but not linked: 1
- Timsit, J., H. Dupont, J. Stahl, A. Tabah, O. Lortholary, C. Martin, A. Francais, B. Guidet, and E. Azoulay. 2009. Use of anitfungal therapy in ICU: a prevalent cohort study in 169 ICUs, abstr. M-1033/523. Abstr. 49th Intersci. Conf. Antimicrob. Chemother. American Society for Microbiology, Washington, DC.
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“As some NAC species exhibit intrinsic resistance to azoles, their use is likely a contributing factor to the more frequent incidence of infections caused by these NAC species (Oxman et al., 2010; Lortholary et al., 2011; Fothergill et al., 2014).”
BackgroundPfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Global trends in the distribution of Candida species causing candidemia
Guinea, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12539 · Cited by 680
Pathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
Pfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101510 · Cited by 396
“parapsilosis as a cause of IC in patients pre-exposed to echinocandins [36,37].”
BackgroundAntifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 394
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Echinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374
“glabrata presenting as the dominant fungal bloodstream pathogen [10].”
de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
“Despite good sensitivity results, first reports demonstrate caution on the usage of echinocandins [100,101].”
ResultSelf-citationMechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
The French Mycosis Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Madec, Y., Denoeud-Ndam, L., Wolff, M., Fontanet, A., Bretagne, S., & Dromer, F. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3408-3 · Cited by 312
Self-citationLockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R., Park, B. J., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01283-12 · Cited by 299
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
“A consequence of enhanced drug exposure is increased selection pressure for resistance and indeed an altered species distribution for invasive infections has been linked to the echinocandin use [8].”
BackgroundPuig-Asensio, M., Padilla, B., Garnacho-Montero, J., Zaragoza, O., Aguado, J. M., Zaragoza, R., Montejo, M., Muñoz, P., Ruiz-Camps, I., Cuenca-Estrella, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12380 · Cited by 299
Update on antifungal resistance in Aspergillus and Candida
Arendrup, M. C. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12513 · Cited by 240
Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
“Often, for naturally susceptible species, both the relative amount of resistant strains and the overall MIC levels in clinical isolates increase after the continuous use of a given antifungal drug [44].”
BackgroundArendrup, M. C., Dzajic, E., Jensen, R. H., Johansen, H. K., Kjaldgaard, P., Knudsen, J. D., Kristensen, L., Leitz, C., Lemming, L. E., Nielsen, L., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12212 · Cited by 206
“parapsilosis after echinocandin exposure [18–21].”
Essential Oils of Lamiaceae Family Plants as Antifungals
Karpiński, T. M. (2020) · Biomolecules · doi:10.3390/biom10010103 · Cited by 202
Timsit, J.-F., Azoulay, E., Schwebel, C., Charles, P. E., Cornet, M., Souweine, B., Klouche, K., Jaber, S., Trouillet, J.-L., Bruneel, F., et al. (2016) · JAMA · doi:10.1001/jama.2016.14655 · Cited by 198
Husain, S., Sole, A., Alexander, B. D., Aslam, S., Avery, R., Benden, C., Billaud, E. M., Chambers, D., Danziger-Isakov, L., Fedson, S., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.007 · Cited by 198
Fluconazole-Resistant Candida albicans Vulvovaginitis
Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K. S., & Sobel, J. D. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827307b2 · Cited by 195
Colombo, A. L., Guimarães, T., Sukienik, T., Pasqualotto, A. C., Andreotti, R., Queiroz-Telles, F., Nouér, S. A., & Nucci, M. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3400-y · Cited by 183
Andes, D. R., Safdar, N., Baddley, J. W., Alexander, B., Brumble, L., Freifeld, A., Hadley, S., Herwaldt, L., Kauffman, C., Lyon, G. M., et al. (2016) · Transplant Infectious Disease · doi:10.1111/tid.12613 · Cited by 182
“parapsilosis, has not been evident in clinical trials.(38,42,43) It is possible that the advanced degree of immunosuppression in this cohort, as suggested by the high rate of both multi-organ failure and allograft rejection, raised the therapeutic hurdle for this”
Invasive candidiasis in critical care: challenges and future directions
Logan, C., Martin-Loeches, I., & Bicanic, T. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06240-x · Cited by 180
Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus
Gonçalves, S. S., Souza, A. C. R., Chowdhary, A., Meis, J. F., & Colombo, A. L. (2016) · Mycoses · doi:10.1111/myc.12469 · Cited by 180
Johnson, M. D., Lewis, R. E., Dodds Ashley, E. S., Ostrosky-Zeichner, L., Zaoutis, T., Thompson, G. R., Andes, D. R., Walsh, T. J., Pappas, P. G., Cornely, O. A., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa394 · Cited by 172
Shields, R. K., Nguyen, M. H., Press, E. G., Kwa, A. L., Cheng, S., Du, C., & Clancy, C. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00027-12 · Cited by 171
Impact of Therapeutic Strategies on the Prognosis of Candidemia in the ICU*
Puig-Asensio, M., Pemán, J., Zaragoza, R., Garnacho-Montero, J., Martín-Mazuelos, E., Cuenca-Estrella, M., & Almirante, B. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000221 · Cited by 147
Auberger, J., Lass-Florl, C., Aigner, M., Clausen, J., Gastl, G., & Nachbaur, D. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks189 · Cited by 155
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
Maubon, D., Garnaud, C., Calandra, T., Sanglard, D., & Cornet, M. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3404-7 · Cited by 165
Eggimann, P., & Pittet, D. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3355-z · Cited by 140
Diagnosis of invasive candidiasis in the ICU
Eggimann, P., Bille, J., & Marchetti, O. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-37 · Cited by 131
Arendrup, M. C., Arikan-Akdagli, S., Jørgensen, K. M., Barac, A., Steinmann, J., Toscano, C., Arsenijevic, V. A., Sartor, A., Lass-Flörl, C., Hamprecht, A., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.08.001 · Cited by 123
The risk and clinical outcome of candidemia depending on underlying malignancy
The French Mycoses Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Desnos-Ollivier, M., Bretagne, S., & Dromer, F. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4743-y · Cited by 134
Self-citationAntifungal stewardship considerations for adults and pediatrics
Hamdy, R. F., Zaoutis, T. E., & Seo, S. K. (2016) · Virulence · doi:10.1080/21505594.2016.1226721 · Cited by 132
ICU-acquired infections in immunocompromised patients
Kreitmann, L., Helms, J., Martín‐Loeches, I., Salluh, J. I., Poulakou, G., Pène, F., & Nseir, S. (2024) · Intensive Care Medicine · doi:10.1007/s00134-023-07295-2 · Cited by 132
Candida spp. with Acquired Echinocandin Resistance, France, 2004–20101
Dannaoui, E., Desnos-Ollivier, M., Garcia-Hermoso, D., Grenouillet, F., Cassaing, S., Baixench, M.-T., Bretagne, S., Dromer, F., Lortholary, O., & the French Mycoses Study Group (2012) · Emerging infectious diseases · doi:10.3201/eid1801.110556 · Cited by 130
Self-citationArendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129
Astvad, K. M. T., Johansen, H. K., Røder, B. L., Rosenvinge, F. S., Knudsen, J. D., Lemming, L., Schønheyder, H. C., Hare, R. K., Kristensen, L., Nielsen, L., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01564-17 · Cited by 125
Warris, A., Pana, Z. D., Oletto, A., Lundin, R., Castagnola, E., Lehrnbecher, T., Groll, A. H., & Roilides, E. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002530 · Cited by 124
What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead
Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx445 · Cited by 98
Invasive fungal disease in PICU: epidemiology and risk factors
Brissaud, O., Guichoux, J., Harambat, J., Tandonnet, O., & Zaoutis, T. (2012) · Annals of Intensive Care · doi:10.1186/2110-5820-2-6 · Cited by 102
Gamaletsou, M. N., Walsh, T. J., Zaoutis, T., Pagoni, M., Kotsopoulou, M., Voulgarelis, M., Panayiotidis, P., Vassilakopoulos, T., Angelopoulou, M. K., Marangos, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12312 · Cited by 112
Treatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade
Tortorano, A. M., Prigitano, A., Lazzarini, C., Passera, M., Deiana, M. L., Cavinato, S., De Luca, C., Grancini, A., Lo Cascio, G., Ossi, C., et al. (2013) · Infection · doi:10.1007/s15010-013-0455-6 · Cited by 110
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Beyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109
Current Epidemiology of Candida Infection
Lockhart, S. R. (2014) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2014.08.001 · Cited by 101
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99
“glabrata represented as the most dominant fungal bloodstream pathogen [30, 61].”
The current treatment landscape: Candidiasis
Bassetti, M., Peghin, M., & Timsit, J.-F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw392 · Cited by 99
Schroeder, M., Weber, T., Denker, T., Winterland, S., Wichmann, D., Rohde, H., Ozga, A.-K., Fischer, M., & Kluge, S. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00755-8 · Cited by 89
Goemaere, B., Becker, P., Van Wijngaerden, E., Maertens, J., Spriet, I., Hendrickx, M., & Lagrou, K. (2018) · Mycoses · doi:10.1111/myc.12714 · Cited by 91
Preventing invasive candida infections. Where could we do better?
Eggimann, P., Que, Y.-A., Revelly, J.-P., & Pagani, J.-L. (2015) · Journal of Hospital Infection · doi:10.1016/j.jhin.2014.11.006 · Cited by 74
Guidelines for Antibiotic Prescription in Intensive Care Unit
Guleria, R., Mohan, A., Kulkarni, A. P., Madan, K., & Hadda, V. (2019) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23101 · Cited by 94
Genetic Drivers of Multidrug Resistance in Candida glabrata
Healey, K. R., Jimenez Ortigosa, C., Shor, E., & Perlin, D. S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01995 · Cited by 93
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Jones, R. N., & Castanheira, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00863-13 · Cited by 85
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Cortegiani, A., Russotto, V., Maggiore, A., Attanasio, M., Naro, A. R., Raineri, S. M., & Giarratano, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004920.pub3 · Cited by 91
Invasive fungal infections in patients with cancer in the Intensive Care Unit
Sipsas, N. V., & Kontoyiannis, D. P. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.11.017 · Cited by 81
Sanglard, D., & Coste, A. T. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02157-15 · Cited by 77
for the S-TAFE study group, Rouzé, A., Loridant, S., Poissy, J., Dervaux, B., Sendid, B., Cornu, M., & Nseir, S. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4932-8 · Cited by 89
Chen, S. C., Sorrell, T. C., Chang, C. C., Paige, E. K., Bryant, P. A., & Slavin, M. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12597 · Cited by 88
Tadec, L., Talarmin, J., Gastinne, T., Bretonnière, C., Miegeville, M., Le Pape, P., & Morio, F. (2016) · Mycoses · doi:10.1111/myc.12470 · Cited by 80
Antifungal use influences Candida species distribution and susceptibility in the intensive care unit
Fournier, P., Schwebel, C., Maubon, D., Vesin, A., Lebeau, B., Foroni, L., Hamidfar-Roy, R., Cornet, M., Timsit, J.-F., & Pelloux, H. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr394 · Cited by 76
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84
Puerta‐Alcalde, P., Monzó, P., Aguilar‐Guisado, M., Ramos, J. C. R., Laporte-Amargós, J., Machado, M., Martín‐Dávila, P., Franch‐Sarto, M., Sánchez‐Romero, I., Badiola, J., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.05.005 · Cited by 85
Puig‐Asensio, M., Ruíz-Camps, I., Fernández‐Ruiz, M., Aguado, J. M., Muñóz, P., Valerio, M., Delgado‐Iribarren, A., Merino, P., Bereciartúa, E., Fortün, J., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.12.027 · Cited by 82
CD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81
Olson, M. L., Jayaraman, A., & Kao, K. C. (2018) · Applied and Environmental Microbiology · doi:10.1128/aem.02769-17 · Cited by 82
Yang, Z.-T., Wu, L., Liu, X.-Y., Zhou, M., Li, J., Wu, J.-Y., Cai, Y., Mao, E.-Q., Chen, E.-Z., & Lortholary, O. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-241 · Cited by 71
Self-citationPosteraro, B., Spanu, T., Fiori, B., De Maio, F., De Carolis, E., Giaquinto, A., Prete, V., De Angelis, G., Torelli, R., D'Inzeo, T., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00285-15 · Cited by 72
The effect of antifungal resistance development on the virulence of Candida species
Bohner, F., Papp, C., & Gácser, A. (2022) · FEMS Yeast Research · doi:10.1093/femsyr/foac019 · Cited by 83
Jensen, R. H., Johansen, H. K., Søes, L. M., Lemming, L. E., Rosenvinge, F. S., Nielsen, L., Olesen, B., Kristensen, L., Dzajic, E., Astvad, K. M. T., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01763-15 · Cited by 77
Candida Bloodstream Infections: Changes in Epidemiology and Increase in Drug Resistance
Kotey, F. C. N., Dayie, N. T. K. D., Tetteh‐Quarcoo, P. B., & Donkor, E. S. (2021) · Infectious Diseases Research and Treatment · doi:10.1177/11786337211026927 · Cited by 77
Coping with Stress and the Emergence of Multidrug Resistance in Fungi
Shor, E., & Perlin, D. S. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004668 · Cited by 71
García‐Ruiz, J. C., López-Soria, L., Olazábal, I., Amutio, E., Arrieta-Aguirre, I., Benito, V. V., Pontón, J., & Moragues, M. D. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.02.004 · Cited by 77
Candidemia in children: Epidemiology, prevention and management
Mantadakis, E., Pana, Z. D., & Zaoutis, T. E. (2018) · Mycoses · doi:10.1111/myc.12792 · Cited by 77
Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy
Forastiero, A., Garcia-Gil, V., Rivero-Menendez, O., Garcia-Rubio, R., Monteiro, M. C., Alastruey-Izquierdo, A., Jordan, R., Agorio, I., & Mellado, E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01005-15 · Cited by 68
Pfaller, M. A., Messer, S. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02481-13 · Cited by 74
A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway
Global Alliance for Infections in Surgery Working Group, Sartelli, M., Kluger, Y., Ansaloni, L., Carlet, J., Brink, A., Hardcastle, T. C., Khanna, A., Chicom-Mefire, A., Rodríguez-Baño, J., et al. (2017) · Surgical Infections · doi:10.1089/sur.2017.219 · Cited by 57
Puerta‐Alcalde, P., & García‐Vidal, C. (2021) · Journal of Fungi · doi:10.3390/jof7100848 · Cited by 72
Occurrence, presentation and treatment of candidemia
Mikulska, M., Del Bono, V., Ratto, S., & Viscoli, C. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.52 · Cited by 71
Investigating Clinical Issues by Genotyping of Medically Important Fungi: Why and How?
Alanio, A., Desnos‐Ollivier, M., Garcia‐Hermoso, D., & Bretagne, S. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00043-16 · Cited by 71
Self-citationAmphotericin B in the Era of New Antifungals: Where Will It Stand?
Akinosoglou, K., Rigopoulos, E. A., Papageorgiou, D., Schinas, G., Polyzou, E., Dimopoulou, E., Gogos, C. A., & Dimοpoulos, G. (2024) · Journal of Fungi · doi:10.3390/jof10040278 · Cited by 69
Shah, D. N., Yau, R., Lasco, T. M., Weston, J., Salazar, M., Palmer, H. R., & Garey, K. W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00019-12 · Cited by 60
Angoulvant, A., Guitard, J., & Hennequin, C. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov114 · Cited by 67
Bretagne, S., Renaudat, C., Desnos‐Ollivier, M., Sitbon, K., Lortholary, O., Dromer, F., & on behalf of the French Mycosis Study Group (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx045 · Cited by 67
Self-citationAntifungal resistance in patients with Candidaemia: a retrospective cohort study
Aldardeer, N. F., Albar, H., Alattas, M., Eldali, A., Qutub, M., Hassanien, A., & Alraddadi, B. M. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-019-4710-z · Cited by 67
Schmalreck, A., Willinger, B., Haase, G., Blum, G., Lass‐Flörl, C., Fegeler, W., Becker, K., & for the Antifungal Susceptibility Testing (AFST) Study Group (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02165.x · Cited by 66
Optimizing antifungal choice and administration
Andes, D. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761135 · Cited by 63
Epidemiología general de la enfermedad fúngica invasora
Pemán, J., & Salavert, M. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2011.09.004 · Cited by 63
Failure of Empirical Systemic Antifungal Therapy in Mechanically Ventilated Critically Ill Patients
Bailly, S., Bouadma, L., Azoulay, É., Garrouste-Orgeas, M., Adrie, C., Souweine, B., Schwebel, C., Maubon, D., Hamidfar-Roy, R., Darmon, M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201409-1701oc · Cited by 64
Zhai, B., Liao, C., Jaggavarapu, S., Tang, Y., Rolling, T., Ning, Y., Sun, T., Bergin, S. A., Gjonbalaj, M., Miranda, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03183-4 · Cited by 62
Metadata
- Authors
- Lortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Institut Pasteur, Unité de Mycologie Moléculaire, Centre National de Référence Mycologie et Antifongiques, Paris
- Centre National de la Recherche Scientifique (FR)
- Institut Pasteur (FR)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-02
- Volume
- 55
- Issue
- 2
- Pages
- 532-538
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3028765
- OpenAlex
- W1981025594
- Cited by
- 362
- References
- 47
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 20 · 2023: 18 · 2022: 18 · 2021: 18 · 2020: 31 · 2019: 16 · 2018: 34 · 2017: 30 · 2016: 23 · 2015: 31 · 2014: 41 · 2013: 24 · 2012: 26
- FWCI
- 11.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Pfizer
- Gilead Sciences
- Astellas Pharma
- Institut Gustave-Roussy
- Institut de Veille Sanitaire
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, caspofungin, fluconazole, Candida species distribution, Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, antifungal susceptibility, reduced susceptibility, fungemia, epidemiology
- MeSH terms
- Caspofungin, Adult, Antifungal Agents, Candida, Candida albicans, Child, Child, Preschool, Cross Infection, France, Humans, Microbial Sensitivity Tests, Paris, Population Surveillance, Prospective Studies, Species Specificity, Fluconazole, Prevalence, Drug Resistance, Fungal, Echinocandins, Lipopeptides, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.